After percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is recommended for 6 months in stable ...

NEW ORLEANS, LA—Among patients with atrial fibrillation (AF) undergoing PCI, 1 month of dual therapy with a direct oral ...

DES, adding clopidogrel in the chronic phase of coronary disease had no ischemic benefit and increased bleeding.

Bristol Myers said that it will halt the study of Milvexian in treating acute coronary syndrome. ・The company will, however, ...

() -Bristol Myers Squibb and Johnson & Johnson said on Friday they would ​stop a late-stage trial of their experimental blood ...

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors—ticagrelor or prasugrel—in people with Type 1 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Researchers evaluated 7,824 consecutive patients (mean ...

The application of antiplatelet therapy in dental surgery has become a focal point for clinicians due to the dual needs of maintaining thrombotic protection while minimising perioperative bleeding ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Antiplatelet therapy appears safe to use ...

WASHINGTON, DC – OCTOBER 12, 2008 – Results of five research studies and a clinical registry first-report presentation scheduled for the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) ...

Patients with mild stroke or high-risk transient ischemic attack (TIA) had a greater benefit from dual antiplatelet therapy if their blood pressure was lower at presentation, a new analysis of the ...